The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Effects of long-term rifampicin administration in primary biliary cirrhosis
Open accessAbstract
The effects of rifampicin treatment (10 mg.kg-1.day-1) on pruritus and cholestasis were evaluated in 16 patients with primary biliary cirrhosis and pruritus followed up for 2-24 months. Assessment of pruritus severity, liver tests, aminopyrine breath test, and bile acids was done at 2 weeks and every 3 months after the beginning of the study. Two patients (12.5%) were withdrawn after 2 months of treatment because they had hepatitis caused by rifampicin. Four patients were withdrawn after 4 months because of liver transplantation (3 cases) and the development of leg edema associated with administration of rifampicin. The remaining 10 patients received therapy for 14.4 +/- 0.7 months and did not experience side effects. Pruritus improved in all patients and disappeared in 11 patients (79%) after 3 months of treatment. Moreover, all patients followed up for more than 1 year were free of pruritus. The alkaline phosphatase level decreased significantly, and the aminopyrine breath test results increased significantly after 2 weeks of treatment (P less than 0.001) and did not change thereafter. In the 9 patients treated for 15 months, alkaline phosphatase levels decreased to 63% of the basal levels and aminopyrine breath test results increased to 153% of baseline values. Transaminases, gamma-glutamyltransferase, and total bile salt levels decreased significantly after 2 weeks of treatment but returned to baseline after 3 months. No changes in bilirubin and cholesterol levels were observed. It is concluded that long-term rifampicin treatment is effective for relieving pruritus in primary biliary cirrhosis, but liver enzymes should be monitored to detect drug-induced hepatitis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Several prospective randomised placebo-controlled trials have shown rifampicin to be effective in the management of cholestatic pruritus.182–185”
From The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines (2018) · cites this paper as [185]
Citations
Cites
A Multicenter, Controlled Trial of Ursodiol for the Treatment of Primary Biliary Cirrhosis
Poupon, R. E., Balkau, B., Eschwège, E., Poupon, R., & the UDCA–PBC Study Group* (1991) · New England Journal of Medicine · doi:10.1056/nejm199105303242204 · Cited by 755
IS URSODEOXYCHOLIC ACID AN EFFECTIVE TREATMENT FOR PRIMARY BILIARY CIRRHOSIS?
Poupon, R. Y., Poupon, R., Calmus, Y., Chrétien, Y., Ballet, F., & Darnis, F. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91610-2 · Cited by 534
The presentation and diagnosis of 100 patients with primary biliary cirrhosis
Sherlock, S., & Scheuer, P. J. (1973) · New England Journal of Medicine · doi:10.1056/nejm197309272891306 · Cited by 504
Christensen, E., Crowe, J., Doniach, D., Pópper, H., Ranek, L., Rodés, J., Tygstrup, N., & Williams, R. L. (1980) · Gastroenterology · doi:10.1016/0016-5085(80)90571-5 · Cited by 271
Self-citationTreatment of pruritus of primary biliary cirrhosis with rifampin
Podesta, A., Lopez, P., Terg, R., Villamil, F., Flores, D., Mastai, R., Udaondo, C. B., & Companc, J. P. (1991) · Digestive Diseases and Sciences · doi:10.1007/bf01300759 · Cited by 267
Treatment of pruritus in primary biliary cirrhosis with rifampin
Ghent, C. N., & Carruthers, S. G. (1988) · Gastroenterology · doi:10.1016/0016-5085(88)90442-8 · Cited by 257
COMPARISON OF RIFAMPICIN WITH PHENOBARBITONE FOR TREATMENT OF PRURITUS IN BILIARY CIRRHOSIS
Bachs, L., Elena, M., Parés, A., Piera, C., & Rodés, J. (1989) · The Lancet · doi:10.1016/s0140-6736(89)91608-5 · Cited by 231
Self-citationRelief of the Pruritus of Jaundice with a Bile-Acid Sequestering Resin
Carey, J. B. (1961) · JAMA · doi:10.1001/jama.1961.03040180034008 · Cited by 134
Phenobarbital Effects in Cholestatic Liver Disease
BLOOMER, J. R., & BOYER, J. L. (1975) · Annals of Internal Medicine · doi:10.7326/0003-4819-82-3-310 · Cited by 120
Rifampin relieves pruritus in children with cholestatic liver disease
Cynamon, H. A., Andres, J. M., & Iafrate, R. P. (1990) · Gastroenterology · doi:10.1016/0016-5085(90)90027-x · Cited by 109
Research works printed but not linked: 2
- Pérez-Ayuso, 1980, Effect of phenobarbital treatment on pruritus and hepatic excretory function in primary biliary cirrhosis (abstr), Gastroenterology, 79, 1119
- Quintero, 1986, Utilidad del recambio plasmático intermitente en la cirrosis biliar primaria, Gastroenterol Hepatol, 9, 329
Cited by
Sorted by citations
Items 101–200 of 235
Characterization and treatment of persistent hepatocellular secretory failure
van Dijk, R., Kremer, A. E., Smit, W. L., van den Elzen, B. D. J., van Gulik, T. M., Gouma, D. J., Laméris, J. S., Bikker, H., Enemuo, V., Stokkers, P. C. F., et al. (2014) · Liver International · doi:10.1111/liv.12603 · Cited by 39
Newer Approaches to the Management of Pruritus in Cholestatic Liver Disease
Düll, M. M., & Kremer, A. E. (2020) · Current Hepatology Reports · doi:10.1007/s11901-020-00517-x · Cited by 42
Medical Treatment of Cholestatic Liver Disease
Paumgartner, G., & Pusl, T. (2008) · Clinics in Liver Disease · doi:10.1016/j.cld.2007.11.013 · Cited by 38
Rifampin Hepatotoxicity Associated With Treatment of Latent Tuberculosis Infection
Fountain, F. F., Tolley, E. A., Jacobs, A. R., & Self, T. H. (2009) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e31818c0134 · Cited by 37
BENIGN RECURRENT INTRAHEPATIC CHOLESTASIS
Luketic, V. A., & Shiffman, M. L. (1999) · Clinics in Liver Disease · doi:10.1016/s1089-3261(05)70083-0 · Cited by 38
Management of Chronic Hepatic Itch
Düll, M. M., & Kremer, A. E. (2018) · Dermatologic Clinics · doi:10.1016/j.det.2018.02.008 · Cited by 35
Lin, Y., Chang, H., Wang, C. C. N., Chu, F.-Y., Shen, H.-Y., Chen, C., & Lim, Y.-P. (2018) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.8b03372 · Cited by 35
Successful treatment of severe unconjugated hyperbilirubinemia via induction of UGT1A1 by rifampicin
Ellis, E. C. S., Wagner, M., Lammert, F., Németh, A., Gumhold, J., Strassburg, C. P., Kylander, C., Katsika, D., Trauner, M. A., Einarsson, C., et al. (2005) · Journal of Hepatology · doi:10.1016/j.jhep.2005.09.011 · Cited by 35
An update on the physiopathology and therapeutic management of cholestatic pruritus in children
Thébaut, A., Debray, D., & Gonzales, E. M. (2017) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2017.08.007 · Cited by 34
Cholestatic pruritus : an update.
Vloo, C. D., & Nevens, F. (2019) · PubMed · Cited by 34
Umeuchi, H., Kawashima, Y., Aoki, C. A., Kurokawa, T., Nakao, K., Itoh, M., Kikuchi, K., Kato, T., Okano, K., Gershwin, M. E., et al. (2005) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2005.06.019 · Cited by 34
Update on the Treatment of the Pruritus of Cholestasis
Bergasa, N. V. (2008) · Clinics in Liver Disease · doi:10.1016/j.cld.2007.11.009 · Cited by 33
Corpechot, C., Chen, P., Wendum, D., Matsuda, F., Barbu, V. D., & Poupon, R. Y. (2006) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.00695.x · Cited by 33
Balsells, F., Wyllie, R., Steffen, R. M., & Kay, M. H. (1997) · Clinical Pediatrics · doi:10.1177/000992289703600809 · Cited by 33
Beuers, U. H., Kullak-Ublick, G. A., Pusl, T., Rauws, E. A., & Rust, C. (2008) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-008-8085-y · Cited by 32
Smith, H. T., de Souza, A. R., Thompson, A. H., McLaughlin, M., Dever, J. J., Myers, J. A., & Chen, J. V. (2023) · Digestive Diseases and Sciences · doi:10.1007/s10620-023-07862-z · Cited by 34
Bolier, R., de Vries, E. S., Parés, A. R., Helder, J., Kemper, E. M., Zwinderman, K. H., Elferink, R. P. J. O., & Beuers, U. H. (2017) · Trials · doi:10.1186/s13063-017-1966-8 · Cited by 32
Self-citationPalmer, M., Regev, A., Lindor, K. D., Avigan, M., Dimick‐Santos, L., Treem, W. R., MARCINAK, J. F., Lewis, J. H., Anania, F. A., Seekins, D. W., et al. (2019) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15579 · Cited by 34
PXR as the tipping point between innate immune response, microbial infections, and drug metabolism
Bautista-Olivier, C. D., & Elizondo, G. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115147 · Cited by 29
Medical Palliation of the Jaundiced Patient with Pruritus
Bergasa, N. V. (2006) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2005.12.008 · Cited by 29
Rifamycins: Strain Improvement Program
Lal, R., Khanna, M., Kaur, H., Srivastava, N., Tripathi, K., & Lal, S. (1995) · Critical Reviews in Microbiology · doi:10.3109/10408419509113532 · Cited by 29
Pruritus and cholestasis: Therapeutic options
Gillespie, D. A., & VICKERS, C. R. (1993) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.1993.tb01510.x · Cited by 27
Clinical Hepatotoxicity. Regulation and Treatment with Inducers of Transport and Cofactors
Marschall, H., Wagner, M., Zollner, G., & Trauner, M. (2007) · Molecular Pharmaceutics · doi:10.1021/mp060133c · Cited by 27
Treatment of Primary Biliary Cirrhosis: Therapy with Choleretic and Immunosuppressive Agents
Silveira, M. G., & Lindor, K. D. (2008) · Clinics in Liver Disease · doi:10.1016/j.cld.2008.02.008 · Cited by 27
Primary Biliary Cirrhosis: New Therapeutic Directions
Berg, C. L., & Gollan, J. L. (1992) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365529209095978 · Cited by 27
Current Landscape and Evolving Therapies for Primary Biliary Cholangitis
Fiorucci, S., Urbani, G., Giorgio, C. D., Biagioli, M., & Distrutti, E. (2024) · Cells · doi:10.3390/cells13181580 · Cited by 28
Parés, A. R. (2018) · Medicina Clínica · doi:10.1016/j.medcli.2017.12.021 · Cited by 26
Self-citationCutaneous Manifestations of Chronic Liver Disease
Patel, A. D., Katz, K. L., & Gordon, K. B. (2020) · Clinics in Liver Disease · doi:10.1016/j.cld.2020.04.003 · Cited by 25
Treatment of the pruritus of cholestasis
Bergasa, N. V. (2004) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-004-0009-1 · Cited by 25
Immunologic Responses and the Pathophysiology of Primary Biliary Cholangitis
Chen, R., Tang, R., Ma, X., & Gershwin, M. E. (2022) · Clinics in Liver Disease · doi:10.1016/j.cld.2022.06.003 · Cited by 26
REVIEWS IN BASIC AND CLINICAL GASTROENTEROLOGY
Lynch, J. P., Metz, D. C., Schuppan, D., Junker, Y., & Barisani, D. (2009) · Cited by 24
Understanding and Treating Pruritus in Primary Biliary Cholangitis
Carrion, A. F., Rosen, J. D., & Levy, C. (2018) · Clinics in Liver Disease · doi:10.1016/j.cld.2018.03.005 · Cited by 24
Simon, F. R. (1998) · Clinics in Liver Disease · doi:10.1016/s1089-3261(05)70023-4 · Cited by 24
Treatment of primary biliary cirrhosis
Poupon, R. Y., & Poupon, R. E. (2000) · Best Practice & Research Clinical Gastroenterology · doi:10.1053/bega.2000.0107 · Cited by 22
Düll, M. M., Wolf, K., Vetter, M., Dietrich, P., Neurath, M. F., & Kremer, A. E. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.641163 · Cited by 21
Bergasa, N. V. (2014) · CRC Press eBooks · doi:10.1201/b16573-10 · Cited by 21
Pruritus in chronic liver disease: Mechanisms and treatment
Bergasa, N. V. (2004) · Current Gastroenterology Reports · doi:10.1007/s11894-004-0020-7 · Cited by 21
Pathogenesis and Treatment of Pruritus Associated with Chronic Kidney Disease and Cholestasis
Kim, J. C., Shim, W., Kwak, I., Lee, D. H., Park, J. S., Lee, S., Kang, S. Y., Chung, B. Y., Park, C. W., & Kim, H. O. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021559 · Cited by 20
Spirulina maxima Protects Liver From Isoniazid and Rifampicin Drug Toxicity
Jatav, S. K., Kulshrestha, A., Zacharia, A., Singh, N., Tejovathi, G., Bisen, P. S., & Prasad, G. B. K. S. (2014) · Journal of Evidence-Based Complementary & Alternative Medicine · doi:10.1177/2156587214530720 · Cited by 20
Use of Butorphanol as Treatment for Cholestatic Itch
Golpanian, R. S., Yosipovitch, G., & Levy, C. (2020) · Digestive Diseases and Sciences · doi:10.1007/s10620-020-06392-2 · Cited by 18
Bergasa, N. V. (1995) · Seminars in Dermatology · doi:10.1016/s1085-5629(05)80052-5 · Cited by 18
The effects of alcohol and illicit drug use on the skin
Jain, N. P., Shao, K., Stewart, C. L., & Grant-Kels, J. M. (2021) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2021.05.005 · Cited by 17
Primary biliary cirrhosis: Clarifying the issues
Sherlock, S. (1994) · The American Journal of Medicine · doi:10.1016/0002-9343(94)90187-2 · Cited by 20
Systematic review: efficacy of therapies for cholestatic pruritus
Ebhohon, E., & Chung, R. T. (2023) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848231172829 · Cited by 16
Patil, A., & Mayo, M. J. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-118-5_9 · Cited by 16
Targeting the pregnane X receptor in liver injury
Li, T., Yu, R. T., Atkins, A. R., Downes, M., Tukey, R. H., & Evans, R. M. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2012.715634 · Cited by 17
Mason, A. L., & Wasilenko, S. T. (2008) · Clinics in Liver Disease · doi:10.1016/j.cld.2008.02.006 · Cited by 16
Parés, A. R. (2018) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2018.07.009 · Cited by 15
Self-citationCarbone, M., Gerussi, A., Cardinale, V., Cazzagon, N., Cossiga, V., Lleò, A., Marrone, G., Marzioni, M., Moschetta, A., Muratori, L., et al. (2024) · Digestive and Liver Disease · doi:10.1016/j.dld.2024.05.002 · Cited by 18
(2012) · PubMed · Cited by 14
Teoh, N., Chitturi, S., & Farrell, G. C. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-6189-2.00086-x · Cited by 14
Treatment of primary biliary cirrhosis
Szalay, F. (2001) · Journal of Physiology-Paris · doi:10.1016/s0928-4257(01)00055-9 · Cited by 14
Asai, Y., Yamamoto, T., & Sato, Y. (2022) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2022.01.024 · Cited by 13
Howard, P. D., Twycross, R., Grove, G. L., Charlesworth, S. A., Mihalyo, M., & Wilcock, A. (2015) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2015.09.004 · Cited by 13
Snodgrass, A., & Motaparthi, K. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-61211-1.00009-7 · Cited by 13
Mawardi, M., Alalwan, A. M., Fallatah, H. I., Abaalkhail, F. A., Hasosah, M. Y., Shagrani, M. A., Alghamdi, M., & Alghamdi, A. (2021) · Saudi Journal of Gastroenterology · doi:10.4103/sjg.sjg_112_21 · Cited by 13
Sadick, N. S. (2001) · Dermatologic Clinics · doi:10.1016/s0733-8635(05)70226-6 · Cited by 12
Kim, S., Michaels, B. D., Kim, G. K., & Rosso, J. Q. D. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4377-2003-7.00008-x · Cited by 11
Ahmed, A., & Mayo, M. J. (2014) · Clinical gastroenterology · doi:10.1007/978-1-4939-1013-7_9 · Cited by 10
Mechanisms and Treatments of Pruritus in Primary Biliary Cholangitis
Shah, R., & Kowdley, K. V. (2019) · Seminars in Liver Disease · doi:10.1055/s-0039-1679918 · Cited by 10
Efficacy of Treatments for Cholestatic Pruritus: A Systemic Review and Meta-analysis
Dervout, C., Boulais, N., Barnetche, T., Nousbaum, J., Brenaut, E., & Misery, L. (2022) · Acta Dermato Venereologica · doi:10.2340/actadv.v102.310 · Cited by 12
Bezafibrate for the Treatment of Cholestatic Pruritus: Time for a Change in Management?
Dyson, J. K., & Jones, D. E. J. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.12.019 · Cited by 10
Itching for Answers: A Comprehensive Review of Cholestatic Pruritus Treatments
Gabrielli, F., Crepaldi, E., Cavicchioli, A., Rivi, M., Costanzo, A. A. C., Cursaro, C., & Andreoné, P. (2024) · Biomolecules · doi:10.3390/biom14101227 · Cited by 11
Cholestatic Pruritus: Pathophysiology, Current Management Approach, and Emerging Therapies
Kode, V., & Yimam, K. K. (2024) · Current Hepatology Reports · doi:10.1007/s11901-024-00638-7 · Cited by 11
Intractable Pruritus in Patients With Hepatitis C Virus
Novelli, G., Rossi, M., Poli, L., Predagostini, R., Iappelli, M., Morabito, V., Lai, Q., Novelli, L., Mennini, G., Corradini, S. G., et al. (2006) · Transplantation Proceedings · doi:10.1016/j.transproceed.2006.03.047 · Cited by 8
Treatment of primary sclerosing cholangitis
Rost, D., Kulaksiz, H., & Stiehl, A. (2007) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-007-0063-6 · Cited by 8
(2016) · Springer Publishing Company eBooks · doi:10.1891/9780826117496.0019 · Cited by 8
Moossavi, M., Hoshyar, R., Hemmati, M., Farahi, A., & Javdani, H. (2016) · Clinical Phytoscience · doi:10.1186/s40816-016-0030-7 · Cited by 8
Song, S., Li, X., Geng, C., Guo, Y., Yang, Y., & Wang, C. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1171512 · Cited by 7
Kumagi, T., & Heathcote, E. J. (2008) · Clinical Journal of Gastroenterology · doi:10.1007/s12328-008-0027-y · Cited by 7
Care of the Cholestatic Patient
Gossard, A. A. (2012) · Clinics in Liver Disease · doi:10.1016/j.cld.2012.11.005 · Cited by 7
Autorinnen/Autoren, & Collaborators (2025) · Zeitschrift für Gastroenterologie · doi:10.1055/a-2558-5204 · Cited by 6
Chronic Inflammation of Liver and Gut
Adler, G. (2009) · Springer eBooks · doi:10.1007/978-1-4020-9353-1 · Cited by 6
Management of Autoimmune and Cholestatic Liver Disorders
Krok, K. L., & Muñoz, S. J. (2009) · Clinics in Liver Disease · doi:10.1016/j.cld.2009.02.011 · Cited by 6
Safety considerations for the management of cholestatic itch
Trivella, J. P., & Levy, C. (2021) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2021.1915984 · Cited by 6
Chazouillères, O., & Housset, C. (2007) · Wiley eBooks · doi:10.1002/9780470691861.ch19a · Cited by 6
Rifampicin Induces Bicarbonate-Rich Choleresis in Rats: Involvement of Anion Exchanger 2
Wang, W., Ren, X., Cai, Y., Chen, L., Zhang, W., & Xu, J. (2015) · Digestive Diseases and Sciences · doi:10.1007/s10620-015-3850-2 · Cited by 5
Drug-induced liver damage with cholestasis
Pereverzev, A. P., Ostroumova, O. D., & Кочетков, А. И. (2020) · Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice · doi:10.37489/2588-0519-2020-3-61-74 · Cited by 7
Antibiotics: unapproved uses or indications
Sadick, N. S. (2000) · Clinics in Dermatology · doi:10.1016/s0738-081x(99)00091-7 · Cited by 5
Primary Sclerosing Cholangitis
Enns, R. A. (2006) · Wiley eBooks · doi:10.1002/9780470986981.ch19 · Cited by 5
Medical treatment of primary sclerosing cholangitis
Lee, Y., & Kaplan, M. M. (1999) · Journal of Hepato-Biliary-Pancreatic Surgery · doi:10.1007/s005340050131 · Cited by 5
Gairola, A., Wetten, A., & Dyson, J. K. (2024) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2024.2343789 · Cited by 4
Han, B., Kim, B.-K., Kim, K., & Fang, S. (2016) · Animal Cells and Systems · doi:10.1080/19768354.2016.1211175 · Cited by 4
Nuclear Receptor Pathways Mediating the Development of Boar Taint
Bone, C., & Squires, E. J. (2022) · Metabolites · doi:10.3390/metabo12090785 · Cited by 4
Management of Patients with Primary Biliary Cirrhosis
Nishio, A., Neuberger, J., & Gershwin, M. E. (1999) · BioDrugs · doi:10.2165/00063030-199912030-00001 · Cited by 4
Ileal Bile Acid Transport Inhibitors for Cholestatic Pruritus: A Primer
Martins, A., & Levy, C. (2025) · Current Hepatology Reports · doi:10.1007/s11901-025-00699-2 · Cited by 4
Bjornsson, E. S. (2014) · Clinical gastroenterology · doi:10.1007/978-1-4939-1013-7_2 · Cited by 3
Bergasa, N. V., & Jones, E. A. (1998) · Clinics in Liver Disease · doi:10.1016/s1089-3261(05)70014-3 · Cited by 3
Current use of anti-infectives in dermatology
Fernández-Obregón, A. C., Rohrback, J. M., Reichel, M. A., & Willis, C. J. (2005) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.3.4.557 · Cited by 3
Singh, N. (2007) · Transplantation · doi:10.1097/01.tp.0000266577.08665.af · Cited by 3
Treatment of primary biliary cirrhosis.
Parés, A. R., & Rodés, J. (2000) · PubMed · Cited by 3
Self-citationManagement Of Primary Sclerosing Cholangitis.
Sandhu, B. S., & Luketic, V. A. (2006) · PubMed · Cited by 3
Liver and Pancreatic Injury Induced by Antituberculous Therapy
Markov, M., Patel, K., Raeesy, A., Bant, A., Thiel, D. H. V., & Nadir, A. (2007) · Digestive Diseases and Sciences · doi:10.1007/s10620-005-9017-9 · Cited by 3
Pregnane X receptor in disease: From xenobiotic sensor to therapeutic target
Gao, Y., Yu, Q., Zhang, L., He, Z., Li, X., Ou, W., Wu, X., Fan, S., & Bi, H. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100133 · Cited by 4
Sebode, M., Bantel, H., Baumann, U., Bufler, P., Demir, M., Dold, L., Keitel, V., Klein, R., Kremer, A. E., Jansen, P. L., et al. (2026) · Zeitschrift für Gastroenterologie · doi:10.1055/a-2769-2475 · Cited by 2
Pruritus, Fatigue, Osteoporosis and Dyslipoproteinemia in Pbc Patients: A Clinician’s Perspective
Dražilová, S., Koky, T., Macej, M., Janíčko, M., Simkova, D., Tsedendamba, A., Комарова, С. Г., & Jarčuška, P. (2024) · Gastroenterology Insights · doi:10.3390/gastroent15020030 · Cited by 2
Rifamycin Antibacterial Agents
Anderson, R. J., Groundwater, P. W., Todd, A., & Worsley, A. J. (2012) · doi:10.1002/9781118325421.ch3 · Cited by 2
Treatment Effect of Rifampicin on Cholestasis
(2005) · The Internet Journal of Pharmacology · doi:10.5580/1bf3 · Cited by 2
Editorial: alleviating the itch—the safety of rifampicin in the real world
Gordon‐Walker, T. T. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14615 · Cited by 2
Primary Sclerosing Cholangitis
Chapman, R. W., & Williamson, K. D. (2017) · Springer eBooks · doi:10.1007/978-3-319-33703-6_52 · Cited by 1
Metadata
- Authors
- Bachs, L., Parés, A., Elena, M., Piera, C., & Rodés, J.
- Affiliations
- Hospital Clínic de Barcelona (ES)
- ORCID
- Parés, Albert
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 1992-06
- Volume
- 102
- Issue
- 6
- Pages
- 2077-2080
- ISSN
- 0016-5085 (ISSN-L)
- OpenAlex
- W1219313770
- Cited by
- 235
- References
- 24
- Citations by year
- 2026: 4 · 2025: 3 · 2024: 8 · 2023: 5 · 2022: 7 · 2021: 5 · 2020: 6 · 2019: 8 · 2018: 10 · 2017: 9 · 2016: 7 · 2015: 12 · 2014: 8 · 2013: 5 · 2012: 7
- FWCI
- 1.83
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Gastroenterology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
- Keywords
- rifampicin, primary biliary cirrhosis, pruritus, cholestasis, drug-induced hepatitis, aminopyrine breath test, alkaline phosphatase, bile acids, long-term drug therapy, adverse drug reactions
- MeSH terms
- Bile Acids and Salts, Cholestasis, Female, Humans, Liver, Liver Cirrhosis, Biliary, Middle Aged, Pruritus, Rifampin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review